Status:

RECRUITING

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Lead Sponsor:

Yale University

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Hallucinations, Auditory

Psychosis

Eligibility:

All Genders

18-65 years

Phase:

EARLY_PHASE1

Brief Summary

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have ...

Detailed Description

Auditory verbal hallucinations (AVH) are present throughout the course of psychotic illness and are among its most distressing symptoms. The presence of hallucinations alone increases risk of suicide ...

Eligibility Criteria

Inclusion

  • Age 18-65
  • English speaking
  • Right handedness
  • Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
  • History of auditory verbal hallucinations occurring at least weekly

Exclusion

  • Current substance dependence or active use as determined by drug test.
  • Any neurological, medical or developmental problem that is known to impair cognition significantly
  • Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia
  • History of seizures
  • History of violence
  • History of suicide
  • Pregnancy (determined by urine pregnancy test)
  • Concurrent participation in any other intervention study
  • History of urinary retention
  • History of delirium
  • Current use of any cholinergic or anticholinergic medication
  • History of asthma, diabetes, and cardiovascular disease
  • Evidence of cardiovascular disease on EKG
  • Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)

Key Trial Info

Start Date :

July 15 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2032

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT04366518

Start Date

July 15 2021

End Date

August 1 2032

Last Update

June 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Connecticut Mental Health Center

New Haven, Connecticut, United States, 06519